|
|
|
News For MNKD From The Last 14 Days Check below for free stories on MNKD the last two weeks. |
|
|
| May 17, 2013 | | 10:25 EDT |  | MNKD | Summer Street says more optimistic on MannKind approval
Summer Street says it is more optimistic that the current trials of MannKind's inhalable insulin Afrezza could lead to FDA approval. The firm notes the product is completing two phase III trials and that it has been skeptical of approval in the past. Summer Street does not have an official rating on shares of MannKind, which are up 22c to $5.38 in early trading. | | | May 9, 2013 | | 16:02 EDT |  | MNKD | MannKind reports Q1 EPS (15c), consensus (15c)
Cash and cash equivalents were $28M at March 31. | |
|
|
|
|
|
|
